The RestoreXL™ is manufactured in the USA by PathRight Medical, located in Orem, Utah.
The RestoreXL™ is marketed by Med'Arte a French company specializing in sales to healthcare institutions of medical devices for Urology.
The RestoreXL™ was designed to recover lost length of the penis following a history of radical prostatectomy or Lapeyronie's disease.
Unlike the standard RestoreX™, it develops only axial traction on the penis whose force, between 2.5 and 3 Kg, is sufficient to overcome atrophy and improve erection quality
✓ The RestoreXL™ was evaluated in patients who had undergone radical prostatectomy causing shortening of the penis ¹ᵇ:
- 94% of patients recovered 1.6 cm of penis length after 6 months' treatment starting 1 month after surgery.
- 73% of patients experienced improved erectile function.
- No adverse events were reported during or after clinical trials.
✓ The clinical study for Lapeyronie's disease shows an increase in penis length of between 2 and 2.2 cm after 6 months of treatment ¹ᵃ
✓ There are no clinical studies on RestoreXL™ to increase the length of small yards and we refrain from communicating information when it has not been clinically validated. We know that RestoreXL™ provides stretching but that it does not provide lengthening because this has not been clinically proven. Only surgery can achieve an increase, a very substantial one, in penis length
Toussi & al.: Efficacy of a Novel Penile Traction Device in Improving Penile Length and Erectile Function Post Prostatectomy: Results from a Single-Center Randomized, Controlled Trial/AUA - The Journal of Urology - August 2021, Volume 206, Issue 2, Page: 416-426
Efficacy of a novel penile traction device in improving penile length and erectile function after prostatectomy: Results from a prospective randomized single-center trial.
Zganjar & al: Efficacy of RestoreX™ Post Prostatectomy: Open-label Phase of a Randomized, Controlled Trial/BJU International - 2023 Aug;132(2):217-226
Efficacy of RestoreX™ in post-prostatectomy: 1st open-access phase of a randomized clinical trial with control group.
Wolters Kluwer: New device helps restore penile length and sexual function after prostate cancer surgery/Newswise - June 1, 2021